Literature DB >> 17873258

The drug facts box: providing consumers with simple tabular data on drug benefit and harm.

Lisa M Schwartz1, Steven Woloshin, H Gilbert Welch.   

Abstract

CONTEXT: Direct-to-consumer drug ads have been criticized for providing inadequate and misleading information. Requiring ads to include a table with data on drug benefits and side effects (derived from clinical trials) could help, provided that consumers understand such tabular information.
OBJECTIVE: To determine if people could understand and use a 9-row x 2-column "study findings table'' presenting expected outcomes (both beneficial and harmful) with and without a drug.
SUBJECTS: A convenience sample of 274 participants: 186 recruited from alumni of Dartmouth's "Community Medical School'' public lecture series and Dartmouth Hitchcock's Center for Shared Decision Making and 88 veterans and their families recruited from waiting rooms in the Veterans Affairs outpatient clinic, White River Junction, Vermont.
DESIGN: Cross-sectional survey. Participants were tested on their comprehension of the study findings table about the drug tamoxifen used for the primary prevention of breast cancer--with no instructions on how to use the table. MAIN OUTCOME MEASURE: Five comprehension questions testing how well participants could read and use the table with drug benefits and side effects data.
RESULTS: On average, participants correctly answered 4 of the 5 table comprehension questions: 89% correctly used the table to determine the percentage of women given tamoxifen who got a blood clot in their legs or lungs, and 71% were able to use data in the table to calculate the absolute difference in the proportion of women who got breast cancer in the tamoxifen v. the placebo group. Most participants were also able to use the table to make comparisons.
CONCLUSION: Most participants--even those with lower formal educational attainment--were able to understand and use the tabular data.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873258     DOI: 10.1177/0272989X07306786

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  36 in total

Review 1.  Molecular therapy of breast cancer: progress and future directions.

Authors:  Sheng-Xiang Lin; Jiong Chen; Mausumi Mazumdar; Donald Poirier; Cheng Wang; Arezki Azzi; Ming Zhou
Journal:  Nat Rev Endocrinol       Date:  2010-07-20       Impact factor: 43.330

2.  Visual presentations of efficacy data in direct-to-consumer prescription drug print and television advertisements: A randomized study.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Kathryn J Aikin; Dhuly Chowdhury; Rebecca R Moultrie; Douglas J Rupert
Journal:  Patient Educ Couns       Date:  2015-12-22

3.  The Drug Facts Box: Improving the communication of prescription drug information.

Authors:  Lisa M Schwartz; Steven Woloshin
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-13       Impact factor: 11.205

4.  Seniors' perceptions of prescription drug advertisements: a pilot study of the potential impact on informed decision making.

Authors:  Jerry L Grenard; Visith Uy; José A Pagán; Dominick L Frosch
Journal:  Patient Educ Couns       Date:  2010-11-01

5.  Do Prescription Drug Ads Tell Consumers Enough About Benefits and Side Effects? Results From the Health Information National Trends Survey, Fourth Administration.

Authors:  Helen W Sullivan; Miriam Campbell
Journal:  J Health Commun       Date:  2015-06-29

6.  Communicating risk in primary care: what the Academy of Medical Sciences' report means in practice.

Authors:  Alexandra Freeman; Martin Marshall; Julian Treadwell; David Spiegelhalter; Imran Rafi
Journal:  Br J Gen Pract       Date:  2017-08       Impact factor: 5.386

7.  Getting to better prescription drug information.

Authors:  Steven Woloshin; Lisa M Schwartz
Journal:  J Gen Intern Med       Date:  2012-12       Impact factor: 5.128

Review 8.  Medication Risk Communication in Rheumatology: Where Are We and Where Do We Go from Here?

Authors:  Susan J Blalock
Journal:  Curr Rheumatol Rep       Date:  2017-02       Impact factor: 4.592

9.  Ethical and epistemic issues in direct-to-consumer drug advertising: where is patient agency?

Authors:  Catherine A Womack
Journal:  Med Health Care Philos       Date:  2013-05

10.  What ever happened to N-of-1 trials? Insiders' perspectives and a look to the future.

Authors:  Richard L Kravitz; Naihua Duan; Edmund J Niedzinski; M Cameron Hay; Saskia K Subramanian; Thomas S Weisner
Journal:  Milbank Q       Date:  2008-12       Impact factor: 4.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.